Legend

Presentation Icons

In Person

On Demand

Live Stream

All times listed are Eastern Standard Time. Program and Faculty are updated often – check back for the most up-to-date information. Click on session name to view session description and component talks.

Type here to filter the list

Sunday, Nov 17th
1:00 PM – 2:00 PM Eastern Time
17S29: Immunotoxicities from Cancer Treatments
Location: Ballroom A
Moderator: Rumey Ishizawar, MD,PhD – University of North Carolina at Chapel Hill
Moderator: Pankti Reid, MD, MPH – University of Chicago Medical Center
Hematologic- and oncologic-associated rheumatic syndromes
CME 1 hours
Sunday, Nov 17th
1:00 PM – 1:30 PM Eastern Time
CAR-T Toxicities and Management
Location: Ballroom A
Speaker: Marco Ruella, MD – University of Pennsylvania
Hematologic- and oncologic-associated rheumatic syndromes
Sunday, Nov 17th
1:30 PM – 2:00 PM Eastern Time
Controversies in Immune-Related Adverse Events Management
Location: Ballroom A
Speaker: Laura Cappelli, MD – Johns Hopkins School of Medicine
Hematologic- and oncologic-associated rheumatic syndromes
Sunday, Nov 17th
3:00 PM – 4:30 PM Eastern Time
17S61: Abstracts: Immunological Complications of Medical Therapy
Location: Room 143ABC
Abstract Moderator: Vibeke Strand, MD – Stanford University School of Medicine, Palo Alto CA
Abstract Moderator: Vanessa Smith, PhD, MD – Ghent University Hospital
Alternate Moderator: Maurizio Cutolo, MD – University of Genova
Alternate Moderator: Ulf Müller-Ladner, MD – JLU Campus KK
Hematologic- and oncologic-associated rheumatic syndromes
CME 0 hours
Sunday, Nov 17th
3:00 PM – 3:15 PM Eastern Time
1725: Exploring Risks of Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA) and Complications While Receiving Immune Checkpoint Inhibitors: Comparative Analysis
Location: Room 143ABC
Presenting Author: Irakli Tskhakaia, MD (he/him/his) – Jefferson Einstein Philadelphia Hospital
Hematologic- and oncologic-associated rheumatic syndromes
Sunday, Nov 17th
3:15 PM – 3:30 PM Eastern Time
1726: Safety, Cancer Progression, and Autoimmune Disease Activity in Patients with Pre-Existing Autoimmune Disease Undergoing CD19 CAR T Cell Therapy for Lymphoma: A Retrospective Comparative Cohort Study
Location: Room 143ABC
Presenting Author: Kathleen Vanni, BA – Brigham and Women's Hospital
Hematologic- and oncologic-associated rheumatic syndromes
Sunday, Nov 17th
3:30 PM – 3:45 PM Eastern Time
1727: Duration of SARS-CoV-2 Viral Shedding After Infection Among Patients with Rheumatic Disease Using Tumor Necrosis Factor Inhibitors or Rituximab
Location: Room 143ABC
Presenting Author: Zachary Wallace, MD;MSc – Massachusetts General Hospital
Hematologic- and oncologic-associated rheumatic syndromes
Sunday, Nov 17th
3:45 PM – 4:00 PM Eastern Time
1728: Higher Oral Steroid Dose Is Associated with Worse Survival in Immune Checkpoint Inhibitor-Treated Rheumatoid Arthritis Patients with Metastatic Non-Small Cell Lung Cancer
Location: Room 143ABC
Presenting Author: Deanna Jannat-Khah, MPH, DrPH – Hospital For Special Surgery
Hematologic- and oncologic-associated rheumatic syndromes
Sunday, Nov 17th
4:00 PM – 4:15 PM Eastern Time
1729: Prophylaxis Against Pneumocystis Jerovecii Pneumonia for Patients with Systemic Autoimmune Diseases: Analysis of the Veterans Affairs Database
Location: Room 143ABC
Presenting Author: Mike Putman, MD, MSc – The Medical College of Wisconsin
Hematologic- and oncologic-associated rheumatic syndromes
Sunday, Nov 17th
4:15 PM – 4:30 PM Eastern Time
1730: Osteoarthritis Is a Risk Factor for Inflammatory Arthritis in Cancer Patients Treated with Immune Checkpoint Inhibitors
Location: Room 143ABC
Presenting Author: Daniel Portnoy, BS – Columbia University Medical Center
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
Immunological Complications of Medical Therapy Poster
Hematologic- and oncologic-associated rheumatic syndromes
CME 0 hours
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1979: Safety and Effectiveness of Immune Checkpoint Inhibitor Therapy in Patients with Pre-existing Autoimmune Disease
Abstract Poster Presenter: Liam O'Neil, MD, MHS – University of Manitoba
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1980: Efficacy and Safety of Methotrexate in Immune Checkpoint Inhibitor-induced Arthritis: A Retrospective Longitudinal Monocentric Study
Abstract Poster Presenter: Elvis Hysa, MD – University of Genoa
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1981: Assessing Major Adverse Cardiovascular Events (MACE) Risk in Common Rheumatology Treatments
Abstract Poster Presenter: Manush Sondhi, MD (he/him/his) – University of Washington
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1982: Comparison of COVID-19 Infection and Mortality Rates in Vaccinated and Unvaccinated Patients with Autoimmune Inflammatory Rheumatic Disease (AIRD) Using Conventional and Biologic DMARD Therapy at an Urban Tertiary Care Hospital
Abstract Poster Presenter: Sarah Ifteqar, MD, FACR – University of Missouri Kansas City
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1983: Immune Checkpoint Inhibitor Associated Vasculitis and Polymyalgia Rheumatica: A Systematic Review
Abstract Poster Presenter: Mats Junek, MD, MSc – McMaster University
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1984: Use of ICD Codes for the Identification of Patients with Immune Checkpoint Inhibitor Induced Inflammatory Arthritis
Abstract Poster Presenter: Tawnie Braaten, MD – UNIVERSITY OF UTAH
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1985: Underlying Autoimmune Disease Has Not Limited Immune Checkpoint Inhibitor Use or Increased Mortality Risk During Cancer Treatment of US Veterans
Abstract Poster Presenter: Madeline O'Sullivan, MD, BS – University of Utah
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1986: Disease Flare Following Immune Checkpoint Inhibition in Patients with Cancer and Preexisting Vasculitis
Abstract Poster Presenter: Juan Sevillano, MD (he/him/his) – MD Anderson Cancer Center
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1988: A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
Abstract Poster Presenter: Marta Cossu, n/a – Janssen Pharmaceutical Research and Development, a Johnson & Johnson company
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1989: Higher Early Cumulative Glucocorticoid Exposure Is Associated with Worse Progression-Free Survival in Patients with Immune Checkpoint Inhibitor Inflammatory Arthritis
Abstract Poster Presenter: Minerva Nong, BA – Columbia University Vagelos College of Physicians and Surgeons
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1990: Human Umbilical Cord Mesenchymal Stem Cell-derived Microvesicles Alleviate Pulmonary Fibrosis by Inhibiting Monocyte-macrophage Migration Through ERK1/2 Signaling-mediated Suppression of CCL2 Expression
Abstract Poster Presenter: Xiuping Liang, PhD (she/her/hers) – West China Hospital, Sichuan University
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1991: Initial Corticosteroid Dosing and Effects on Disease Activity, Survival, and Tumor Progression in Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Abstract Poster Presenter: Muhammad Hamza Bukhari, MBBS – Howard County General Hospital
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1992: Gout FlaresFollowingImmune Checkpoint Inhibitors Treatment
Abstract Poster Presenter: Austen Herron, MD (he/him/his) – University of Utah
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1993: Identification of Elevated Soluble Factors in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Their Association with Severity and Persistence
Abstract Poster Presenter: Elise Gray-Gaillard, BS – Johns Hopkins University
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1994: Clinical Patterns and Long-term Outcomes of Arthritis Triggered by Immune Checkpoint Inhibitors. A Multicenter Study
Abstract Poster Presenter: Javier Narvaez, PhD – Hospital Universitario de Bellvitge
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1995: Use of Abatacept for the Treatment of Severe Immune-related Adverse Events from Immune Checkpoint Inhibitors for Cancer: A Case Series
Abstract Poster Presenter: Kaitlin McCarter, MD (she/her/hers) – Brigham and Women's Hospital
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1996: Granulomatous Reactions in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Literature Review
Abstract Poster Presenter: Elizabeth Wang, MD – Weill Cornell
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1997: Features of interleukin-1 and interleukin-6 Inhibitor (IL-1i/IL-6i) Related Severe Delayed Adverse Reactions in Subjects with or Without Reaction-risk Associated HLA-DRB1*15
Abstract Poster Presenter: Vivian Saper, MD – Stanford University
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1998: Association Between Small Interfering RNA Therapy and Autoimmune Diseases: U.S. Prospective Cohort Study
Abstract Poster Presenter: Liang Sien Chen, n/a (he/him/his) – Chang Gung Memorial Hospital, Linkou Branch
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1999: Effects of JAK Inhibitors on Subsets of the Innate Immune System
Abstract Poster Presenter: Carmen Lasa Teja, MD – Hospital Universitario Marqués de Valdecilla
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
2000: Induction of Systemic Inflammatory Diseases with Dupilumab Therapy
Abstract Poster Presenter: Jeanne Tisseau des Escotais, n/a – Cochin
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
2001: Complications and Treatment Use Associated with Long-term Oral Corticosteroid Therapy Among Patients with Dermatomyositis or Polymyositis
Abstract Poster Presenter: Rohit Aggarwal, MD;MS (he/him/his) – Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
2002: Pain and Physical Function, but Not Fatigue, Track with Disease Activity in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Abstract Poster Presenter: Laura Cappelli, MD – Johns Hopkins School of Medicine
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
2003: Cumulative Incidence of Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis in Lung Cancer Patients with and Without Hip Osteoarthritis and Impacts on Survival
Abstract Poster Presenter: Laura Cappelli, MD – Johns Hopkins School of Medicine
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
2004: Rheumatic Complications Post-CAR-T Cell Therapy. Experience of a Single Center
Abstract Poster Presenter: Jose A. Gomez-Puerta, MD,PhD,MPH – Hospital Clínic
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 18th
10:30 AM – 12:30 PM Eastern Time
1976: Post-Hoc Analysis of Clinically Relevant Anti-Vaccine Antibodies in Participants with Rheumatoid Arthritis Treated with Nipocalimab
Abstract Poster Presenter: Faye Yu, BSc – Johnson & Johnson Innovative Medicine
Hematologic- and oncologic-associated rheumatic syndromes